PROTAC Building Blocks

By Alberta Research Chemicals

Targeted protein degradation (TDP) has been an attractive concept in the drug discovery to selectively remove the disease-causing proteins from the system, and remained as academic interest for several decades until the recent discovery of small molecule proteolysis-targeting chimera (PROTAC) protein degraders.

This PROTAC technology has been widely used both in academia and industry in the last 20 years and in 2020, provided the first clinical proof-of-concept.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.